7Baggers

Maravai LifeSciences Holdings, Inc
(NASDAQ:MRVI) 

MRVI stock logo

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutica...

Founded: 2014
CEO: Carl W. Hull  
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 
                          
      revenue
    		65,837,000 49,866,000 41,630,000 47,397,000 46,850,000 56,406,000 65,200,000 73,400,000 64,179,000 74,141,000 66,865,000 68,914,000 79,025,000 204,713,000 191,263,000 242,732,000 244,293,000 228,444,000 204,810,000 217,775,000 148,211,000  
      yoy
    		40.53% -11.59% -36.15% -35.43% -27.00% -23.92% -2.49% 6.51% -18.79% -63.78% -65.04% -71.61% -67.65% -10.39% -6.61% 11.46% 64.83%      
      qoq
    		32.03% 19.78% -12.17% 1.17% -16.94% -13.49% -11.17% 14.37% -13.44% 10.88% -2.97% -12.79% -61.40% 7.03% -21.20% -0.64% 6.94% 11.54% -5.95% 46.94%   
      cost of revenue
    		32,136,000 37,024,000 35,975,000 39,629,000 39,125,000 37,444,000 36,826,000 38,271,000 38,335,000 35,108,000 36,686,000 43,273,000 33,676,000 53,253,000 38,176,000 37,496,000 40,032,000 40,633,000 32,047,000 37,513,000 30,368,000  
      gross profit
    		33,701,000 12,842,000 5,655,000                    
      yoy
    		                      
      qoq
    		162.43% 127.09%                     
      gross margin %
    		51.19% 25.75% 13.58% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%  
      operating expenses:
    		                      
      selling, general and administrative
    		29,092,000 31,583,000 35,396,000 38,575,000 39,564,000 41,243,000 39,087,000 40,556,000 40,885,000 38,478,000 38,864,000 35,377,000 38,671,000 37,203,000 30,795,000 28,061,000 33,200,000 27,553,000 25,189,000 24,085,000 23,237,000  
      research and development
    		3,889,000 3,788,000 3,844,000 4,882,000 4,888,000 4,561,000 4,344,000 5,284,000 5,032,000 4,594,000 4,347,000 4,194,000 4,145,000 5,011,000 5,389,000 4,274,000 3,695,000 9,173,000 1,950,000 1,932,000 2,164,000  
      goodwill impairment
    		 10,721,000  30,449,000 12,435,000 11,912,000 154,239,000                
      restructuring
    		2,878,000 10,441,000 7,386,000   6,000 -4,000 -4,000 -1,212,000              
      total operating expenses
    		35,859,000 71,637,000 46,686,000 113,675,000 96,012,000 94,536,000 234,314,000 82,912,000 83,040,000 81,291,000 82,282,000 80,528,000 76,492,000 95,467,000 74,360,000 62,031,000 76,927,000 77,359,000 47,937,000 63,530,000 55,769,000  
      income from operations
    		-2,158,000 -58,795,000 -41,031,000 -66,278,000 -49,162,000 -38,130,000 -169,114,000 -9,512,000 -18,861,000 -7,150,000 -15,417,000 -11,614,000 2,533,000 109,246,000 116,903,000 180,701,000 167,366,000 151,085,000 156,873,000 154,245,000 92,442,000  
      yoy
    		-95.61% 54.20% -75.74% 596.78% 160.65% 433.29% 996.93% -18.10% -844.61% -106.54% -113.19% -106.43% -98.49% -27.69% -25.48% 17.15% 81.05%      
      qoq
    		-96.33% 43.29% -38.09% 34.82% 28.93% -77.45% 1677.90% -49.57% 163.79% -53.62% 32.74% -558.51% -97.68% -6.55% -35.31% 7.97% 10.78% -3.69% 1.70% 66.86%   
      operating margin %
    		-3.28% -117.91% -98.56% -139.84% -104.93% -67.60% -259.38% -12.96% -29.39% -9.64% -23.06% -16.85% 3.21% 53.37% 61.12% 74.44% 68.51% 66.14% 76.59% 70.83% 62.37%  
      other income:
    		                      
      interest expense
    		-5,749,000 -6,555,000 -6,844,000 -6,815,000 -6,778,000 -11,263,000 -13,634,000 -11,939,000 -10,864,000 -15,400,000 -11,637,000 -7,022,000 -11,833,000 -10,180,000 -3,136,000 -4,434,000 -2,664,000 -4,433,000 -8,545,000 -8,512,000 -8,770,000  
      interest income
    		1,873,000 2,384,000 2,797,000 3,030,000 3,225,000 6,036,000 7,071,000 7,086,000 7,210,000 7,459,000 7,432,000 6,791,000 6,045,000          
      other income
    		-494,000 -1,027,250 -71,000  24,000 -596,000 72,000  106,000 49,000 66,000  168,000 914,000 -4,000  7,000 201,000 78,000 -3,000 3,000  
      income before income taxes
    		-6,528,000 -63,009,000 -45,149,000 -74,125,000 -52,691,000 -46,502,000 -175,644,000 -16,927,000 -22,409,000 656,186,000 -20,563,000 -13,364,000 -4,523,000 95,876,000 113,763,000 174,992,000 166,841,000 143,822,000 151,652,000 145,730,000 89,561,000  
      income tax expense
    		-151,000 6,000 -92,000  162,000 -7,000 311,000  271,000 766,168,000 -5,461,000 -1,421,000 -3,175,000 8,447,000 14,110,000 18,271,000 19,981,000 17,578,000 18,842,000 11,386,000 13,709,000  
      net income
    		-6,377,000 -63,015,000 -45,057,000 -69,837,000 -52,853,000 -46,495,000 -175,955,000 -14,492,000 -22,680,000 -109,982,000 -15,102,000 -11,943,000 -1,348,000 87,429,000 99,653,000 156,721,000 146,860,000 126,244,000 132,810,000 134,344,000 75,852,000  
      yoy
    		-87.93% 35.53% -74.39% 381.90% 133.04% -57.72% 1065.11% 21.34% 1582.49% -225.80% -115.15% -107.62% -100.92% -30.75% -24.97% 16.66% 93.61%      
      qoq
    		-89.88% 39.86% -35.48% 32.13% 13.67% -73.58% 1114.15% -36.10% -79.38% 628.26% 26.45% 785.98% -101.54% -12.27% -36.41% 6.71% 16.33% -4.94% -1.14% 77.11%   
      net income margin %
    		-9.69% -126.37% -108.23% -147.34% -112.81% -82.43% -269.87% -19.74% -35.34% -148.34% -22.59% -17.33% -1.71% 42.71% 52.10% 64.57% 60.12% 55.26% 64.85% 61.69% 51.18%  
      net loss attributable to non-controlling interests
    		-2,644,000 -27,334,000 -19,501,000 -30,246,000 -22,908,000 -23,606,500 -76,917,000 -6,907,000 -10,602,000              
      net loss attributable to maravai lifesciences holdings, inc.
    		-3,733,000 -35,681,000 -25,556,000 -39,591,000 -29,945,000 -29,675,250 -99,038,000 -7,585,000 -12,078,000              
      net loss per class a common share attributable to maravai lifesciences holdings, inc., basic and diluted
    		-20 -240 -180 -270 -210 -217.5 -700 -50 -90              
      weighted-average number of class a common shares outstanding, basic and diluted
    		146,426,000 144,360,000 144,683,000 144,236,000 143,425,000  141,555,000 135,842,000 132,333,000              
      change in estimated fair value of contingent consideration
    		  60,000 140,000  -630,000 -178,000 -1,195,000  -3,355,000 2,385,000 -2,316,000    -7,800,000       
      change in payable to related parties pursuant to the tax receivable agreement
    		     -1,000 -39,000   671,228,000 -1,007,000 101,000 -1,436,000 -6,442,000         
      other expense
    		   -4,062,000    -2,562,000    -1,620,000    -1,275,000       
      income tax benefit
    		   -4,288,000    -2,435,000               
      loss on extinguishment of debt
    		                -208,000      
      net income attributable to non-controlling interests
    		         -4,023,000 -8,640,000 -5,402,000 -1,281,000 49,795,000 55,184,000 85,481,000 79,998,000 70,803,000 78,536,000 85,269,000 52,605,000  
      net income attributable to maravai lifesciences holdings, inc.
    		         -105,959,000 -6,462,000 -6,541,000 -67,000 37,634,000 44,469,000 71,240,000 66,862,000 55,441,000 54,274,000 49,075,000 23,247,000  
      net income per class a common share attributable to maravai lifesciences holdings, inc.:
    		                      
      basic
    		         -800 -50 -50  280 340 540 510 430 460 440 240  
      diluted
    		         -800 -50 -50  300 340 530 500 420 450 440 240  
      weighted-average number of class a common shares outstanding:
    		                      
      basic
    		     137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 131,545,000 131,540,000 131,524,000 131,489,000 114,791,000 118,433,000 112,203,530,000 96,646,515,000  
      diluted
    		     137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 255,323,000 131,651,000 255,361,000 255,287,000 257,803,000 258,028,000 112,280,375,000 96,672,968,000  
      gain on sale of business
    		                  -11,249,000    
      change in payable to related parties pursuant to a tax receivable agreement
    		                2,340,000 -3,031,000 3,246,000  5,886,000  
      gain on sale and leaseback transaction
    		                      
      net income per class a common share/unit attributable to maravai lifesciences holdings, inc.:
    		                      
      basic
    		         -800 -50 -50  280 340 540 510 430 460 440 240  
      diluted
    		         -800 -50 -50  300 340 530 500 420 450 440 240  
      weighted-average number of class a common shares/units outstanding:
    		                      
      basic
    		     137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 131,545,000 131,540,000 131,524,000 131,489,000 114,791,000 118,433,000 112,203,530,000 96,646,515,000  
      diluted
    		     137,906,000    131,919,000 131,930,000 131,864,000 131,739,000 255,323,000 131,651,000 255,361,000 255,287,000 257,803,000 258,028,000 112,280,375,000 96,672,968,000  
                          
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 
                            
        assets
      		                      
        current assets:
      		                      
        cash and cash equivalents
      		165,922,000 216,890,000 243,574,000 269,907,000 285,053,000 322,399,000 578,157,000 573,171,000 561,691,000 574,962,000 579,605,000 580,176,000 628,273,000 632,138,000 617,446,000 550,676,000 431,469,000 551,272,000 547,898,000 374,710,000 247,675,000 236,184,000 
        accounts receivable
      		33,415,000 25,498,000 22,537,000 27,882,000 28,493,000 38,520,000 28,873,000 38,651,000 36,685,000 54,605,000 45,674,000 48,987,000 56,273,000 138,624,000 114,069,000 120,354,000 120,355,000 117,512,000 65,939,000 83,534,000 121,821,000 51,018,000 
        inventory
      		40,462,000 40,495,000 45,326,000 46,667,000 49,773,000 50,082,000 50,409,000 49,294,000 49,846,000 51,397,000 49,142,000 47,402,000 54,819,000 43,152,000 62,424,000 60,113,000 51,409,000 51,557,000 56,246,000 47,781,000 47,129,000 33,301,000 
        prepaid expenses and other current assets
      		11,937,000 13,368,000 14,430,000 15,305,000 12,963,000 18,145,000 21,659,000 17,063,000 16,818,000 17,830,000 22,916,000 22,515,000 25,532,000 25,798,000 23,432,000 19,664,000 15,902,000 19,698,000 17,395,000 13,432,000 8,918,000 11,095,000 
        total current assets
      		251,736,000 296,251,000 325,867,000 359,761,000 376,282,000 429,146,000 679,098,000 685,362,000 667,884,000 699,912,000 700,865,000 699,312,000 765,513,000 847,902,000 835,526,000 759,382,000 619,135,000 740,039,000 687,478,000 644,491,000 425,543,000 331,598,000 
        property and equipment
      		146,930,000 151,479,000 158,624,000 162,727,000 166,428,000 164,474,000 164,555,000 165,503,000 161,628,000 162,900,000 153,565,000 141,619,000 87,721,000 52,694,000 48,420,000 46,956,000 47,702,000 46,332,000 108,322,000 104,751,000 105,133,000 101,305,000 
        goodwill
      		129,429,000 129,429,000 129,429,000 129,429,000 159,878,000 159,878,000 171,790,000 326,029,000 326,029,000 326,029,000 326,029,000 326,459,000 326,569,000 283,668,000 283,535,000 283,535,000 283,535,000 152,766,000 152,766,000 152,766,000 224,275,000 224,275,000 
        intangible assets
      		144,887,000 151,543,000 185,876,000 193,066,000 199,581,000 194,957,000 201,858,000 207,249,000 214,118,000 220,987,000 227,856,000 234,726,000 241,578,000 216,663,000 222,899,000 229,153,000 235,405,000 117,571,000 121,225,000 125,116,000 172,616,000 177,656,000 
        other assets
      		40,235,000 41,875,000 49,395,000 51,983,000 57,582,000 59,789,000 60,914,000 63,465,000 74,982,000 77,622,000 85,579,000 92,735,000 127,035,000 115,589,000 87,399,000 72,419,000 64,243,000 53,451,000 4,106,000 4,026,000 4,300,000 4,158,000 
        total assets
      		713,217,000 770,577,000 849,191,000 896,966,000 959,751,000 1,008,244,000 1,278,215,000 1,447,608,000 1,444,641,000 1,487,450,000 2,267,553,000 2,264,437,000 2,315,388,000 2,282,315,000 2,248,899,000 2,171,799,000 2,043,230,000 1,918,276,000 1,894,683,000 1,601,247,000 1,351,768,000 1,270,691,000 
        liabilities and stockholders’ equity
      		                      
        current liabilities:
      		                      
        accounts payable
      		8,535,000 2,910,000 7,998,000 11,525,000 9,525,000 11,957,000 9,494,000 12,536,000 8,226,000 10,729,000 9,424,000 6,658,000 4,784,000 5,991,000 9,459,000 23,267,000 10,384,000 8,154,000 8,917,000 11,704,000 9,806,000 8,171,000 
        accrued expenses and other current liabilities
      		28,647,000 36,567,000 48,136,000 50,202,000 44,603,000 36,407,000 38,498,000 40,719,000 35,405,000 60,237,000 56,042,000 50,344,000 70,065,000 53,371,000 60,187,000 43,641,000 32,411,000 34,574,000 31,422,000 24,794,000 28,973,000 38,546,000 
        current portion of long-term debt
      		5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 5,440,000 6,000,000 6,000,000 6,000,000 6,000,000 6,000,000 
        total current liabilities
      		42,622,000 44,917,000 61,574,000 69,682,000 63,158,000 56,971,000 63,241,000 68,552,000 59,022,000 87,468,000 78,253,000 74,919,000 124,896,000 110,144,000 115,655,000 112,530,000 86,675,000 93,777,000 114,352,000 164,773,000 165,252,000 130,778,000 
        long-term debt, less current portion
      		235,571,000 286,331,000 287,381,000 288,436,000 289,499,000 290,492,000 516,283,000 517,083,000 517,893,000 518,707,000 519,520,000 520,336,000 521,161,000 521,997,000 522,824,000 523,655,000 524,499,000 524,591,000 525,584,000 526,583,000 527,593,000 528,614,000 
        finance lease liabilities, less current portion
      		29,869,000 30,141,000 30,407,000 30,651,000 30,881,000 31,106,000 31,327,000 31,527,000 31,714,000 31,897,000 32,077,000 32,236,000           
        other long-term liabilities
      		36,072,000 36,477,000 37,970,000 38,186,000 43,966,000 52,466,000 54,237,000 54,032,000 58,623,000 59,494,000 64,531,000 62,862,000 66,052,000 68,975,000 57,519,000 50,590,000 66,522,000 41,066,000 1,553,000 1,057,000 2,310,000 2,231,000 
        total liabilities
      		344,134,000 397,866,000 417,332,000 428,983,000 429,478,000 431,035,000 665,088,000 671,194,000 667,252,000 697,566,000 1,375,272,000 1,366,799,000 1,414,750,000 1,377,072,000 1,407,230,000 1,398,007,000 1,388,928,000 1,372,915,000 1,441,067,000 1,268,106,000 1,142,012,000 1,115,945,000 
        commitments and contingencies
      		                      
        stockholders’ equity:
      		                      
        class a common stock
      		1,475,000 1,453,000 1,447,000 1,446,000 1,440,000 1,420,000 1,416,000 1,415,000 1,327,000 1,322,000 1,319,000 1,319,000 1,318,000 1,317,000 1,315,000 1,315,000 1,315,000 1,315,000 1,314,000 1,143,000 966,000 966,000 
        class b common stock
      		1,107,000 1,107,000 1,107,000 1,107,000 1,107,000 1,107,000 1,107,000 1,107,000 1,191,000 1,191,000 1,191,000 1,191,000 1,191,000 1,237,000 1,237,000 1,237,000 1,237,000 1,237,000 1,262,000 1,433,000 1,610,000 1,610,000 
        additional paid-in capital
      		202,131,000 199,177,000 196,511,000 191,377,000 186,797,000 181,874,000 175,581,000 168,337,000 134,482,000 128,503,000 125,088,000 119,903,000 114,309,000 137,898,000 134,077,000 131,373,000 128,584,000 128,386,000 172,611,000 118,208,000 85,976,000 85,125,000 
        retained earnings
      		6,385,000 10,118,000 45,799,000 71,355,000 110,946,000 140,891,000 167,036,000 266,074,000 273,659,000 285,737,000 391,696,000 398,158,000 404,699,000 404,766,000 367,132,000 322,663,000 251,423,000 184,561,000 127,450,000 73,176,000 24,101,000 854,000 
        accumulated other comprehensive income
      		466,000 524,000 579,000 574,000 324,000                  
        total stockholders’ equity attributable to maravai lifesciences holdings, inc.
      		211,564,000 212,379,000 245,443,000 265,859,000 300,614,000 325,292,000 345,140,000 436,933,000 410,659,000 416,753,000 519,294,000 520,571,000 521,517,000 545,218,000 503,761,000        
        non-controlling interest
      		157,519,000 160,332,000 186,416,000 202,124,000 229,659,000 251,917,000 267,987,000 339,481,000 366,730,000 373,131,000 372,987,000 377,067,000 379,121,000 360,025,000 337,908,000 317,204,000 271,743,000 229,862,000 150,979,000    
        total stockholders’ equity
      		369,083,000 372,711,000 431,859,000 467,983,000 530,273,000 577,209,000 613,127,000 776,414,000 777,389,000 789,884,000 892,281,000 897,638,000 900,638,000 905,243,000 841,669,000        
        total liabilities and stockholders’ equity
      		713,217,000 770,577,000 849,191,000 896,966,000 959,751,000 1,008,244,000 1,278,215,000 1,447,608,000 1,444,641,000 1,487,450,000 2,267,553,000 2,264,437,000 2,315,388,000 2,282,315,000 2,248,899,000        
        deferred revenue
      		   1,639,000 2,756,000 2,375,000 1,834,000 2,078,000 2,210,000 3,360,000 2,553,000 2,459,000 2,053,000 3,088,000 5,822,000 5,435,000 3,693,000 10,211,000 66,715,000 109,490,000 119,175,000 78,061,000 
        current portion of finance lease liabilities
      		   876,000 834,000 792,000 750,000 710,000 672,000 633,000 596,000 560,000           
        deferred tax liabilities
      		   2,028,000 1,974,000      6,690,000 8,512,000 8,680,000        8,571,000 8,609,000 
        interest rate cap
      		       6,575,000               
        current portion of payable to related parties pursuant to the tax receivable agreement
      		      7,225,000 7,069,000 7,069,000 7,069,000 4,198,000 9,458,000 42,254,000 42,254,000 34,747,000        
        government funding receivable
      		       608,000 2,844,000 1,118,000 3,528,000 232,000 616,000 8,190,000 18,155,000 8,575,000       
        deferred tax assets
      		          773,659,000 769,586,000 766,972,000 765,799,000 771,120,000 780,354,000 793,210,000 808,117,000 820,786,000 570,097,000 419,901,000 431,699,000 
        payable to related parties pursuant to the tax receivable agreement, less current portion
      		          674,201,000 667,934,000 677,392,000 675,956,000 711,232,000        
        current portion of finance lease obligations
      		            300,000          
        finance lease obligations, less current portion
      		            16,569,000          
        liabilities and stockholders' equity
      		                      
        current portion of payable to related parties pursuant to a tax receivable agreement
      		               34,747,000 34,747,000 34,838,000 1,298,000 1,298,000   
        payable to related parties pursuant to a tax receivable agreement, less current portion
      		               711,232,000 711,232,000 713,481,000     
        stockholders' equity:
      		                      
        total stockholders' equity attributable to maravai lifesciences holdings, inc.
      		               456,588,000 382,559,000 315,499,000 302,637,000 193,921,000 112,611,000  
        total stockholders' equity
      		               773,792,000 654,302,000 545,361,000 453,616,000 333,141,000 209,756,000  
        total liabilities and stockholders' equity
      		               2,171,799,000 2,043,230,000 1,918,276,000 1,894,683,000 1,601,247,000 1,351,768,000  
        lease facility financing obligation, less current portion
      		                  55,324,000 55,626,000 55,924,000 56,167,000 
        accumulated other comprehensive loss
      		                   -39,000 -42,000 -44,000 
        payable to related parties pursuant to a tax receivable agreement
      		                  744,254,000 520,067,000 382,362,000 389,546,000 
        lease commitments
      		                      
        assets held for sale
      		                   125,034,000   
        liabilities related to assets held for sale
      		                   11,487,000   
        non-controlling interests
      		                   139,220,000 97,145,000 66,235,000 
        current portion of payable to related parties pursuant to tax receivable agreement
      		                    1,298,000  
        stockholders' equity
      		                      
        liabilities and stockholders'/member’s equity
      		                      
        stockholders' / member's equity
      		                      
        member’s equity
      		                      
        total stockholders' / member's equity attributable to maravai lifesciences holdings, inc.
      		                     88,511,000 
        total stockholders' / member’s equity
      		                     154,746,000 
        total liabilities and stockholders' / member’s equity
      		                     1,270,691,000 
        revenue
      		                     284,098,000 
        operating expenses:
      		                      
        cost of revenue
      		                     79,649,000 
        research and development
      		                     9,304,000 
        selling, general and administrative
      		                     94,245,000 
        change in estimated fair value of contingent consideration
      		                      
        gain on sale and leaseback transaction
      		                     -19,002,000 
        total operating expenses
      		                     164,196,000 
        income from operations
      		                     119,902,000 
        other income:
      		                      
        interest expense
      		                     -30,740,000 
        loss on extinguishment of debt
      		                     -7,592,000 
        other income
      		                     126,000 
        income before income taxes
      		                     81,696,000 
        income tax benefit
      		                     2,880,000 
        net income
      		                     78,816,000 
        net (loss) attributable to non-controlling interests
      		                     -10,156,000 
        net income attributable to maravai lifesciences holdings, inc.
      		                     88,972,000 
        net income per class a common share/unit attributable to maravai lifesciences holdings, inc.:
      		                      
        basic
      		                     7,430 
        diluted
      		                     2,360 
        weighted-average number of class a common shares/units outstanding:
      		                      
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
                             
          operating activities:
        		                     
          net loss
        		-6,377,000 -63,015,000 -45,057,000 -69,837,000 -52,853,000  -175,955,000 -14,492,000 -22,680,000             
          adjustments to reconcile net loss to net cash from operating activities:
        		                     
          depreciation
        		4,900,000 5,933,000 5,975,000 5,957,000 5,693,000 5,466,000 5,044,000 5,556,000 4,786,000 3,932,000 4,071,000 2,815,000 2,080,000 1,962,000 1,857,000 1,892,000 1,855,000 -210,000 2,472,000 2,297,000 1,854,000 
          amortization of intangible assets
        		6,472,000 6,512,000 7,209,000 7,200,000 7,030,000 6,902,000 6,891,000 6,869,000 6,869,000 6,869,000 6,870,000 6,852,000 6,765,000 6,236,000 6,254,000 6,252,000 5,527,000 3,654,000 4,604,000 5,041,000 5,040,000 
          amortization of operating lease right-of-use assets
        		1,606,000 2,288,000 2,259,000 2,229,000 2,187,000 2,158,000 2,104,000 2,122,000 2,098,000 2,179,000 2,155,000           
          stock-based compensation expense
        		6,743,000 3,926,000 9,056,000 6,789,000 10,403,000 10,545,000 13,050,000 13,763,000 12,057,000  9,987,000 9,272,000 5,987,000  4,740,000       
          impairment
        		605,000                     
          other
        		541,000 -1,079,000 334,000 1,193,000 -236,000 -645,000 1,349,000 -94,000 223,000 2,161,000 -985,000 -4,041,000 552,000 -2,464,000 -4,246,000 -298,000 -985,000 594,000 -486,000 -245,000 -144,000 
          changes in operating assets and liabilities, net of acquisitions:
        		                     
          accounts receivable
        		-7,914,000 -2,961,000 5,116,000 501,000 10,160,000 -11,345,000 9,842,000 -2,021,000 17,883,000 -8,785,000 3,212,000 7,561,000 82,407,000 -25,774,000 5,834,000 -115,000 -2,217,000 -51,540,000 17,620,000 34,341,000 -70,812,000 
          inventory
        		33,000 3,092,000 1,350,000 3,108,000 449,000 327,000 -1,521,000 751,000 820,000 -2,184,000 -1,495,000 7,711,000 -3,383,000 19,273,000 -2,312,000 -8,703,000 1,201,000 4,689,000 -8,190,000 -4,245,000 -13,828,000 
          prepaid expenses and other current assets
        		1,433,000   -2,862,000 2,241,000                 
          accounts payable
        		6,162,000 -5,515,000 -2,906,000 1,782,000 -708,000 2,254,000 -2,420,000 4,571,000 -3,682,000 1,659,000 1,986,000 1,874,000 -235,000 -3,468,000 -4,420,000 4,360,000 1,950,000 -867,000 -2,542,000 2,188,000 1,897,000 
          accrued expenses and other current liabilities
        		-5,336,000 -13,514,000 1,514,000 5,917,000 1,457,000 -1,636,000 1,000 2,997,000 -24,116,000 6,146,000 2,380,000 -17,643,000 24,225,000 -5,611,000 15,887,000 2,289,000 -4,062,000 6,619,000 3,840,000 -2,872,000 -11,044,000 
          other long-term liabilities
        		-203,000 -1,893,000 -2,060,000 -6,188,000 -8,490,000 -1,150,000 -298,000 -3,725,000 -1,126,000 -1,640,000 -1,084,000 -2,651,000 -10,603,000 2,079,000 991,000 1,868,000 -1,109,000 -4,788,000 268,000 279,000 -280,000 
          net cash from operating activities
        		8,665,000 -22,768,000 -15,150,000 -10,265,000 -9,390,000 -14,638,000 13,136,000 17,434,000 -8,467,000 7,790,000 14,166,000 19,194,000 85,074,000 99,335,000 110,059,000 164,279,000 162,304,000 58,167,000 105,856,000 165,832,000 38,715,000 
          capital expenditures
        		-4,437,000 -2,114,000 -2,926,000 -2,874,000 -5,235,000 -5,849,000 -8,591,000 -9,553,000 -5,665,000 -16,799,000 -15,827,000 -25,059,000 -7,868,000 -6,214,000 -6,467,000 -1,661,000 -2,748,000 -5,662,000 -1,406,000 -4,202,000 -3,580,000 
          free cash flows
        		4,228,000 -24,882,000 -18,076,000 -13,139,000 -14,625,000 -20,487,000 4,545,000 7,881,000 -14,132,000 -9,009,000 -1,661,000 -5,865,000 77,206,000 93,121,000 103,592,000 162,618,000 159,556,000 52,505,000 104,450,000 161,630,000 35,135,000 
          investing activities:
        		                     
          cash paid for acquisitions of a business, net of cash acquired
        		 0 0 -362,000 -18,628,000                 
          purchases of property and equipment
        		-4,437,000 -2,114,000 -2,926,000 -2,874,000 -5,235,000 -5,849,000 -8,591,000 -9,553,000 -5,665,000 -16,799,000 -15,827,000 -25,059,000 -7,868,000 -6,214,000 -6,467,000 -1,661,000 -2,748,000 -5,662,000 -1,406,000 -4,202,000 -3,580,000 
          net cash from investing activities
        		-4,437,000 -2,114,000 -2,926,000 -3,236,000 -23,129,000 -4,931,000 -8,959,000 -6,182,000 -4,244,000 -12,903,000 -15,520,000 -24,157,000 -69,730,000 -18,520,000 -5,847,000 -1,661,000 -241,584,000 -5,662,000 118,551,000 -4,202,000 -3,032,000 
          financing activities:
        		                     
          principal repayments of long-term debt
        		-51,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -230,313,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -1,360,000 -9,815,000 -1,500,000 -1,500,000 -1,500,000 -1,500,000 
          other financing activities
        		-3,866,000                     
          net cash from financing activities
        		-55,226,000 -1,816,000 -8,249,000 -1,534,000 -4,900,000 -236,189,000 809,000 228,000 -560,000 470,000 783,000 -43,134,000 -19,209,000 -66,123,000 -37,442,000 -43,411,000 -40,523,000 -48,998,000 -51,501,000 -34,351,000 -24,199,000 
          effects of exchange rate changes on cash and cash equivalents
        		30,000  -8,000 -111,000 73,000                 
          net decrease in cash and cash equivalents
        		-50,968,000   -15,146,000 -37,346,000   11,480,000 -13,271,000             
          cash and cash equivalents, beginning of period
        		216,890,000 0 0 0 322,399,000 0 0 0 574,962,000 0 0           
          cash and cash equivalents, end of period
        		165,922,000 -26,684,000 -26,333,000 -15,146,000 285,053,000 -255,758,000 4,986,000 11,480,000 561,691,000 -4,643,000 -571,000           
          supplemental cash flow information:
        		                     
          cash paid for interest
        		6,146,000   6,119,000 6,518,000    12,140,000 12,068,000   9,593,000   4,759,000 1,373,000 4,204,000 7,483,000 7,600,000 7,947,000 
          cash paid for income taxes
        		    139,000           12,942,000 914,000 5,904,000 7,482,000 6,362,000 2,725,000 
          supplemental disclosures of non-cash activities:
        		                     
          property and equipment included in accounts payable and accrued expenses
        		248,000         -1,692,000       1,742,000   -55,000 1,415,000 
          fair value of contingent consideration liability recorded in connection with acquisition of a business
        		         0            
          accrued consideration payable recorded in connection with acquisitions of a business
        		                     
          amortization of deferred financing costs
        		 403,000 399,000 391,000 461,000 658,000 754,000 744,000 740,000 743,000 738,000 729,000 719,000 654,000 724,000 711,000 699,000 681,000 676,000 665,000 654,000 
          loss on extinguishment of debt
        		             0 0 0 208,000     
          deferred income taxes
        		         764,750,000 -5,532,000 -2,756,000 -1,520,000 7,011,000 9,234,000 12,856,000 13,217,000 17,466,000 11,227,000 6,451,000 11,760,000 
          change in estimated fair value of contingent consideration
        		     -630,000 -178,000   -3,355,000 2,385,000   0 0       
          revaluation of liabilities under the tax receivable agreement
        		     1,000    -671,228,000 1,007,000 -101,000 1,436,000 6,442,000 0 0 -2,340,000     
          acquisition related tax adjustment
        		 0 0                   
          other assets
        		                     
          proceeds from government assistance allocated to property and equipment
        		 0 0 0 734,000 1,718,000 632,000 3,371,000 1,421,000 3,896,000 307,000 634,000 8,028,000         
          other investing activities
        		                     
          refunds (distributions) for tax liabilities to non-controlling interests holder
        		                     
          financing costs paid to acquire long-term debt
        		                     
          proceeds from interest rate cap agreement
        		 0 0 0 1,375,000 2,225,000                
          payments of acquisition related contingent consideration and consideration holdback
        		 0                    
          payments pursuant to the tax receivable agreement
        		                     
          effects of exchange rate changes on cash
        		                 -133,000 32,000 6,000 7,000 
          cash (refunded) paid for income taxes
        		         90,000            
          accrued receivable for capital expenditures to be reimbursed under a government contract
        		         -2,410,000            
          right-of-use assets obtained in exchange for finance lease liabilities
        		                     
          right-of-use assets obtained in exchange for operating lease liabilities
        		                     
          goodwill impairment
        		  0 30,449,000 12,435,000 11,912,000                
          change in fair value of derivative instruments
        		        -1,919,000             
          prepaid expenses and other current and noncurrent assets
        		     996,000                
          purchase of technology
        		     -500,000                
          distributions for tax liabilities to non-controlling interest holder
        		      0               
          payments of finance lease liabilities
        		  -200,000 -187,000 -183,000 -180,000 -160,000 -148,000 -145,000 -142,000 -124,000           
          taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of class a common stock
        		  111,000 13,000 -4,732,000   -28,000 -1,433,000             
          net increase in cash and cash equivalents
        		     -255,758,000    -4,643,000            
          deferred revenue
        		   -1,116,000 381,000 540,000 -244,000 -132,000 -1,150,000 808,000 94,000 406,000 -1,058,000 -2,735,000 388,000 1,742,000 -6,518,000 -56,505,000 -42,776,000 -9,684,000 41,114,000 
          net income
        		         -109,982,000 -15,102,000 -11,943,000 -1,348,000 87,429,000 99,653,000 156,721,000 146,860,000 126,244,000 132,810,000 134,344,000 75,852,000 
          adjustments to reconcile net income to net cash from operating activities:
        		                     
          cash paid for acquisition, net of cash acquired
        		                     
          acquisition deposit
        		                     
          prepaid lease payments on finance lease yet to commence
        		            -159,000         
          proceeds from sale of business, net of cash divested
        		             0    0    
          distributions to non-controlling interests holders
        		                     
          proceeds from borrowings of long-term debt, net of discount
        		                     
          payment of acquisition consideration holdback
        		         0 0 0 -9,706,000         
          payments to mlsh 1 pursuant to the tax receivable agreement
        		         0 0           
          payments to mlsh 2 pursuant to the tax receivable agreement
        		         0 0           
          (taxes paid for shares withheld) proceeds from issuance of class a common stock under employee equity plans
        		     -602,000                
          cash paid (refunded) for income taxes
        		                     
          accrued consideration payable for mychem acquisition
        		                     
          cash paid for acquisition of a business, net of cash acquired
        		          0 109,000 -69,731,000  0 0 -238,836,000     
          changes in operating assets and liabilities:
        		                     
          prepaid expenses and other assets
        		       -199,000 730,000 6,375,000 3,479,000 21,294,000 -23,012,000 -16,498,000 -26,323,000 -12,569,000 2,517,000 -1,923,000 -2,577,000 -5,111,000 98,000 
          proceeds from derivative instruments
        		       2,336,000 2,378,000 2,323,000 1,955,000 1,398,000 492,000         
          distributions for tax liabilities to non-controlling interest holders
        		          0           
          equity-based compensation expense
        		                3,627,000 2,230,000 3,567,000 2,383,000 2,278,000 
          gain on sale of business
        		                 0    
          government funding receivable
        		                     
          proceeds from sale of building
        		                 0 0 0 548,000 
          shares withheld for employee taxes, net of proceeds from issuance of class a common stock under employee equity plans
        		            -333,000         
          right-of-use assets obtained in exchange for new finance lease liabilities
        		         0            
          right-of-use assets obtained in exchange for new operating lease liabilities
        		         0       773,000     
          recognition of deferred tax assets as a result of exchanges of llc units and cash contribution
        		                     
          recognition of liabilities under the tax receivable agreement
        		                     
          proceeds from borrowings of long-term debt
        		              0 0 8,455,000     
          proceeds from issuance of class a common stock under employee equity plans, net of shares withheld for employee taxes
        		          312,000           
          amortization of right-of-use assets
        		            2,062,000 1,831,000 1,798,000       
          distributions for tax liabilities to non-controlling interests holders
        		            -8,302,000  -36,812,000 -42,588,000 -39,889,000  -50,095,000 -33,075,000 -23,128,000 
          net decrease in cash
        		            -3,865,000         
          cash, beginning of period
        		            632,138,000 0 0 0 551,272,000 0 0 0 236,184,000 
          cash, end of period
        		            628,273,000 14,692,000 66,770,000 119,207,000 431,469,000 3,374,000 173,188,000 127,035,000 247,675,000 
          gain on sale and leaseback transaction
        		                     
          acquired and in-process research and development costs
        		                     
          financing costs incurred for line of credit
        		                     
          financing costs incurred for long-term debt
        		                     
          repurchase of incentive units
        		                     
          payment of contingent consideration
        		                     
          payments made on facility financing lease obligation and capital lease
        		                  -217,000 -224,000 -141,000 
          payment for non-controlling interests in mlsc
        		                     
          payment to mlsh 2 for blocker mergers
        		                     
          proceeds from issuance of class a common stock sold in ipo, net of offering costs
        		                     
          proceeds from issuance of class b common stock sold to mlsh 1
        		                     
          purchase of llc units from mlsh 1
        		                     
          repurchase of class a common stock from mlsh 2
        		                     
          net increase in cash
        		             14,692,000 66,770,000 119,207,000 -119,803,000 3,374,000 173,188,000   
          financing cost deducted from long-term debt proceeds
        		                     
          building and improvements capitalized under lease financing transaction
        		                     
          exchange of units for mlsc non-controlling interests
        		                     
          exchange of class a common stock for the blocker mergers
        		                     
          recognition of deferred tax assets from organizational transactions, subsequent exchanges and cash contribution
        		                     
          ipo issuance costs included in accounts payable and accrued expenses
        		                     
          receivable from lessor funded financing
        		                     
          proceeds from employee stock purchase plan and exercise of stock options, net of shares withheld for employee taxes
        		              730,000 537,000 726,000     
          net increase in cash including cash classified within current assets held for sale
        		                     
          less: net increase in cash classified within current assets held for sale
        		                     
          non-cash operating lease expense
        		                1,874,000     
          supplemental disclosures of non-cash investing and financing activities:
        		                     
          operating activities
        		                     
          loss on long-term debt refinancing
        		                     
          revaluation of liabilities payable to related parties pursuant to a tax receivable agreement
        		                     
          investing activities
        		                     
          cash paid for asset acquisition, net of cash acquired
        		                     
          financing activities
        		                     
          supplemental cash flow information
        		                     
          supplemental disclosures of non-cash investing and financing activities
        		                     
          building and improvements capitalized under lease financing transactions
        		                     
          property and equipment under new capital lease
        		                     
          revaluation of liabilities under tax receivable agreement
        		                  -3,246,000 0 -5,886,000 
          proceeds from employee stock purchase plan
        		                  311,000 448,000 570,000 
          non-cash interest expense recognized on lease facility financing obligation
        		                   0 162,000 
          recognition of liabilities under tax receivable agreement
        		                     
          recognition of deferred tax assets as a result of exchange of llc units
        		                     
          net increase in cash, and restricted cash
        		                    11,491,000 
          change in provision for doubtful accounts
        		                     
          earn-out liability
        		                     
          working capital adjustment for acquisition in prior year
        		                     
          acquisition of patents
        		                     
          recognition of deferred tax assets from organizational transactions